Type 2 Diabetes

According to the Center for Disease Control (CDC), 18.8 million people have been diagnosed with diabetes. Type 2 diabetes accounts for about 95% of diagnosed diabetes patients. Per the CDC, up to 74% of those with Type 2 diabetes are pre-insulin dependent. This means that the patients still have a functioning pancreas and thus could potentially benefit from treatment with MABp1. Consequently, there are at least about 13 million people in the U.S. that could potentially benefit from MABp1.